The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as

Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines.

When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The

Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.

Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals